Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety & Efficacy of 68Ga-DOTATOC PET/CT in Somatostatin Receptor Positive Tumors
NCT01619865Phase 2Completed
- Start
- Feb 2012
- Primary completion
- Aug 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium Ga 68-edotreotide in Neuroendocrine Neoplasm (NEN), Carcinoid Tumor (CT), neuroblastoma and 2 more. Primary endpoints: Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent at 24 hours and Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOC at 6 months. Started Feb 2012; status: completed.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)Carcinoid Tumor (CT)neuroblastomamedulloblastomapheochromocytoma
Beyond the preview
Go deeper on NCT01619865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01619865.